Information on EC 2.3.2.13 - protein-glutamine gamma-glutamyltransferase

New: Word Map on EC 2.3.2.13
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Mark a special word or phrase in this record:
Search Reference ID:
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)


The expected taxonomic range for this enzyme is: Bacteria, Eukaryota

EC NUMBER
COMMENTARY hide
2.3.2.13
-
RECOMMENDED NAME
GeneOntology No.
protein-glutamine gamma-glutamyltransferase
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
protein glutamine + alkylamine = protein N5-alkylglutamine + NH3
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
aminoacyl group transfer
-
-
-
-
SYSTEMATIC NAME
IUBMB Comments
protein-glutamine:amine gamma-glutamyltransferase
Requires Ca2+. The gamma-carboxamide groups of peptide-bound glutamine residues act as acyl donors, and the 6-amino-groups of protein- and peptide-bound lysine residues act as acceptors, to give intra- and inter-molecular N6-(5-glutamyl)-lysine crosslinks. Formed by proteolytic cleavage from plasma Factor XIII
CAS REGISTRY NUMBER
COMMENTARY hide
80146-85-6
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
adult female parasite, responsible for human lymohatic filariasis
-
-
Manually annotated by BRENDA team
comparison of enzyme expression in normal tissue and spontaneous tumours
-
-
Manually annotated by BRENDA team
Hartley strain
-
-
Manually annotated by BRENDA team
pigeon
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
comparison of enzyme expression in normal tissue and spontaneous tumours
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
cultivar Golden Delicious
-
-
Manually annotated by BRENDA team
8 distinct transglutaminase isoenzymes have been identified on the genomic level, 6 have been isolated and characterized: factor XIII, type 1 or keratinocyte transglutaminase, type 2 or tissue transglutaminase, type 3 or epidermal transglutaminase, type 4 or prostate transglutaminase and type 5 transglutaminase
-
-
Manually annotated by BRENDA team
-
SwissProt
Manually annotated by BRENDA team
scallop
-
-
Manually annotated by BRENDA team
Mus musculus BALB/c
BALB/c strain
-
-
Manually annotated by BRENDA team
newborn, CF57 strain
-
-
Manually annotated by BRENDA team
Nemipterus sp.
-
-
-
Manually annotated by BRENDA team
Merino sheep
-
-
Manually annotated by BRENDA team
red sea bream
-
-
Manually annotated by BRENDA team
; enzyme has GTPase and ATPase activity
SwissProt
Manually annotated by BRENDA team
isozymes from hemocyte and muscle
-
-
Manually annotated by BRENDA team
pea, var. Kelvedon wonder
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
Rattus norvegicus male Sasco/King (SD)BR
male Sasco/King (SD)BR strain
-
-
Manually annotated by BRENDA team
WSH03-13
-
-
Manually annotated by BRENDA team
strain 40847
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
; expression in Streptomyces lividans
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
japanese horseshoe crab
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
malfunction
-
transglutaminase 2 (TG2) mutations are associated with diabetes type 2. Lack of TG2 reduces glucose-stimulated insulin secretion from the pancreatic islets
physiological function
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
1-N-(carbobenzoxy-L-glutaminylglycyl)-5-N-(5'-N',N'-dimethylamino-1'-naphthalenesulfonyl)diamidopentane + alpha-carbobenzoxy-lysine
?
show the reaction diagram
1-N-(carbobenzoxy-L-glutaminylglycyl)-5-N-(5'-N',N'-dimethylamino-1'-naphthalenesulfonyl)diamidopentane + alpha-S1-casein
?
show the reaction diagram
1-N-(carbobenzoxy-L-glutaminylglycyl)-5-N-(5'-N',N'-dimethylamino-1'-naphthalenesulfonyl)diamidopentane + butylamine
?
show the reaction diagram
1-N-(carbobenzoxy-L-glutaminylglycyl)-5-N-(5'-N',N'-dimethylamino-1'-naphthalenesulfonyl)diamidopentane + ethylamine
?
show the reaction diagram
1-N-(carbobenzoxy-L-glutaminylglycyl)-5-N-(5'-N',N'-dimethylamino-1'-naphthalenesulfonyl)diamidopentane + propylamine
?
show the reaction diagram
10-kDa heat shock protein-bound gamma-glutamine + methylamine
10-kDa heat shock protein N5-methylglutamine + NH3
show the reaction diagram
-
-
-
-
?
2-N-benzoyloxycarbonyl-L-Lys-NH-CH2-CH2-NH-dansyl + Abeta1-40
?
show the reaction diagram
-
residues 1-40 of beta-amyloid protein
-
-
?
2-N-benzoyloxycarbonyl-L-Lys-NH-CH2-CH2-NH-dansyl + N-methyl-casein
?
show the reaction diagram
-
-
-
-
?
60-kDa heat shock protein-bound gamma-glutamine + methylamine
60-kDa heat shock protein N5-methylglutamine + NH3
show the reaction diagram
-
-
-
-
?
Ac-PQLPF-NH2 + putrescine
?
show the reaction diagram
-
-
-
-
?
actin + ?
?
show the reaction diagram
-
-
-
-
?
actin-bound gamma-glutamine + methylamine
actin N5-methylglutamine + NH3
show the reaction diagram
-
-
-
-
?
alpha-actin-bound gamma-glutamine + methylamine
alpha-actin N5-methylglutamine + NH3
show the reaction diagram
-
-
-
-
?
alpha-difluoroornithine + casein
?
show the reaction diagram
-
suicide substrate
-
-
?
alpha-lactalbumin + carbobenzoxy-L-glutaminylglycine
?
show the reaction diagram
-
-
-
-
?
alpha-lactalbumin + dansylcadaverine
?
show the reaction diagram
-
-
-
-
?
alpha-N-t-butyloxycarbonyl-L-Lys-CH2-CH2-dansyl + N,N-dimethylcasein
?
show the reaction diagram
-
-
-
-
-
alphaB-crystallin + ?
?
show the reaction diagram
-
-
formation of water-insoluble dimers or polymers
-
?
alphaN-Boc-Lys-NH-CH2-CH2-NH-dansyl + Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val
?
show the reaction diagram
-
i.e. beta-amyloid protein peptide comprising residues 1-40
-
-
?
alphaN-Boc-Lys-NH-CH2-CH2-NH-dansyl + N,N-dimethylated casein
?
show the reaction diagram
-
transpeptidation
-
-
?
apomyoglobin + carbobenzoxy-L-glutaminylglycine
?
show the reaction diagram
-
-
-
-
?
apomyoglobin + dansylcadaverine
?
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-L-glutaminglycine + glycine ethyl ester
benzyloxycarbonyl-alpha-L-glutamyl(gamma-glycine ethyl ester)glycine + NH3
show the reaction diagram
-
-
-
r
benzyloxycarbonyl-Pro-Gln-Nle-Phe + H2O
?
show the reaction diagram
-
-
-
-
?
beta-casein + glycine ethylester
?
show the reaction diagram
-
-
-
-
?
betaB2-crystallin + ?
?
show the reaction diagram
-
-
formation of water-insoluble dimers or polymers
-
?
biotinyl-5-pentylamine + N,N'-dimethylcasein
?
show the reaction diagram
-
covalent incorporation of biotinyl-5-pentylamine into N,N'-dimethylcasein
-
-
?
biotinylated TVQQEL + calcium binding protein S100A7
?
show the reaction diagram
-
transglutaminase 2
-
-
?
CBP40 + ?
?
show the reaction diagram
-
a 40 kDa Ca2+-binding protein accumulating most significantly around injured areas
-
-
?
Cbz-L-Gln-Gly + ?
?
show the reaction diagram
-
-
-
-
-
Cbz-L-Gln-Gly + alkylamine
?
show the reaction diagram
-
-
-
-
?
Cbz-L-Glu(gamma-p-nitrophenyl ester)-Gly + ?
?
show the reaction diagram
Cbz-Phe-GABA umbelliferyl ester + ?
?
show the reaction diagram
-
-
-
-
?
chlathrin heavy chain-bound gamma-glutamine + methylamine
clathrin heavy chain N5-methylglutamine + NH3
show the reaction diagram
-
-
-
-
?
cytoskeletal 1 keratin type II-bound gamma-glutamine + methylamine
cytoskeletal 1 keratin type II N5-methylglutamine + NH3
show the reaction diagram
-
-
-
-
?
cytoskeletal 2 epidermal keratin type II-bound gamma-glutamine + methylamine
cytoskeletal 2 epidermal keratin type II N5-methylglutamine + NH3
show the reaction diagram
-
-
-
-
?
cytoskeletal 5 keratin type II-bound gamma-glutamine + methylamine
cytoskeletal 5 keratin type II N5-methylglutamine + NH3
show the reaction diagram
-
-
-
-
?
cytoskeletal 6A keratin type II-bound gamma-glutamine + methylamine
cytoskeletal 6A keratin type II N5-methylglutamine + NH3
show the reaction diagram
-
-
-
-
?
dansylcadaverine + N,N-dimethylcasein
?
show the reaction diagram
-
-
-
-
?
DQMMLPWPAVAL + spermine
?
show the reaction diagram
-
specific substrate of factor XIII
-
-
?
EAQQIVM + monodansylcadaverine
?
show the reaction diagram
-
liver transglutaminase, peptide derived from the N-terminal sequence of fibronection, first modified residue is mainly Q3
-
-
?
exendin 4 + 5-biotinamidopentylamine
?
show the reaction diagram
-
-
modification at residues K12 and K27 of exendin 4
-
?
fibrinogen-bound gamma-glutamine + 5-(biotinamido)pentylamine
fibrinogen N5-(biotinamido)pentyl-glutamine + NH3
show the reaction diagram
-
-
-
-
?
fibronectin-bound gamma-glutamine + 5-biotinamidopentylamine
fibronectin N5-biotinamidopentylglutamine + NH3
show the reaction diagram
-
-
-
-
?
fibronectin-bound gamma-glutamine + alkylamine
fibronectin N5-alkylglutamine + NH3
show the reaction diagram
-
-
-
?
filamin A-bound gamma-glutamine + methylamine
filamin A N5-methylglutamine + NH3
show the reaction diagram
-
-
-
-
?
fluorescein-4-isothiocyanate-beta-AQG + NK6-AP
fluorescein-4-isothiocyanate-labeled NK6-AP + ?
show the reaction diagram
NK6-AP, recombinant Escherichia coli alkaline phosphatase with a N-terminal fused acyl-acceptor substrate peptide tag MKHKGS
-
-
-
fluorescein-4-isothiocyanate-epsilon-aminocaproate-QG + NK6-AP
fluorescein-4-isothiocyanate-labeled NK6-AP + ?
show the reaction diagram
NK6-AP, recombinant Escherichia coli alkaline phosphatase with a N-terminal fused acyl-acceptor substrate peptide tag MKHKGS
-
-
-
galectin-3-bound gamma-glutamine + methylamine
galectin-3 N5-methylglutamine + NH3
show the reaction diagram
-
-
-
-
?
GTP + H2O
GDP + phosphate
show the reaction diagram
H2A histone type 1-bound gamma-glutamine + methylamine
H2A histone type 1 N5-methylglutamine + NH3
show the reaction diagram
-
-
-
-
?
H2B histone type 1-bound gamma-glutamine + methylamine
H2B histone type 1 N5-methylglutamine + NH3
show the reaction diagram
-
-
-
-
?
H4 histone -bound gamma-glutamine + methylamine
H4 histone N5-methylglutamine + NH3
show the reaction diagram
-
-
-
-
?
histamine + acetyl-alphaS1-casein
?
show the reaction diagram
-
-
-
-
?
histamine + maleyl-bovine serum albumin
?
show the reaction diagram
-
-
-
-
?
HQSYVDPWMLDH + spermine
?
show the reaction diagram
-
specific substrate of factor XIII
-
-
?
hydroxylamine + carbobenzoxy-Gln-Gly
carbobenzoxy-Gln-Gly-hydroxamate + ?
show the reaction diagram
-
other substrates are carbobenzoxy-Gln-Gln-Gly, carbobenzoxy-Gly-Gln-Gln-Gly, carbobenzoxy-Gly-Gly-Gln-Gly with 38%, 13% and 28% efficiency, respectively
-
?
leishmanolysin + alkylamine
?
show the reaction diagram
-
-
-
-
?
LGPQSKVIG + glycine-ethylester
?
show the reaction diagram
-
i.e. K9, an optimized sequence based on beta-casein
-
-
?
LGPQSLVIG + glycine ethylester
?
show the reaction diagram
-
i.e. K9(K7L), a modified optimized sequence based on beta-casein
-
-
?
methylamine + succinyl-beta-casein
?
show the reaction diagram
-
transglutaminase B
-
-
?
mono-6-amino-6-deoxy-alpha-cyclodextrin + bovine pancreatic trypsin
?
show the reaction diagram
-
-
-
-
?
mono-6-amino-6-deoxy-beta-cyclodextrin + bovine pancreatic trypsin
?
show the reaction diagram
-
-
-
-
?
mono-6-amino-6-deoxy-gamma-cyclodextrin + bovine pancreatic trypsin
?
show the reaction diagram
-
-
-
-
?
monodansylcadaverine + N,N'-dimethylated casein
?
show the reaction diagram
Nemipterus sp.
-
-
-
-
?
monodansylcadaverine + N,N-dimethylcasein
?
show the reaction diagram
monodansylcadaverine + succinylated casein
?
show the reaction diagram
-
-
-
-
?
myo-inositol-1-phosphate synthase + alkylamine
?
show the reaction diagram
-
-
-
-
?
N,N-dimethyl-1,4-phenylenediamine + CBz-Gln-Ala
?
show the reaction diagram
-
-
-
-
?
N,N-dimethyl-1,4-phenylenediamine + Cbz-Gln-Gly
?
show the reaction diagram
N,N-dimethyl-1,4-phenylenediamine + CBz-Gln-Gly-Gly
?
show the reaction diagram
-
-
-
-
?
N,N-dimethyl-1,4-phenylenediamine + CBz-Gln-Leu
?
show the reaction diagram
-
-
-
-
?
N,N-dimethyl-1,4-phenylenediamine + CBz-Gln-Phe
?
show the reaction diagram
-
-
-
-
?
N,N-dimethyl-1,4-phenylenediamine + CBz-Gln-Ser
?
show the reaction diagram
-
-
-
-
?
N,N-dimethyl-1,4-phenylenediamine + CBz-Gln-Val
?
show the reaction diagram
-
-
-
-
?
N,N-dimethylated casein-bound gamma-glutamine + dansyl-labeled amine nucleophile
?
show the reaction diagram
-
-
-
-
?
N,N-dimethylcasein + putrescine
?
show the reaction diagram
-
-
-
-
?
N-(5-aminopentyl)-5-dimethylamino-1-naphthalenesulfonamide + casein
?
show the reaction diagram
N-(5-aminopentyl)-5-dimethylamino-1-naphthalenesulfonamide + F-actin
?
show the reaction diagram
N-(5-aminopentyl)biotinamide + N,N'-dimethylcasein
?
show the reaction diagram
-
-
-
-
?
N-acetyl-PNPQLPF + alkylamine
?
show the reaction diagram
-
-
-
-
?
N-carbobenzoxy-L-glutaminyl-glycine + ovalbumin
?
show the reaction diagram
-
-
-
-
?
N-carbobenzoxy-L-glutaminylglycine + NH2OH
hydroxamic acid + ?
show the reaction diagram
N-carbobenzoxy-L-glutaminylglycine + NH2OH
L-glutamic acid-gamma-monohydroxamate + ?
show the reaction diagram
-
specific high-affinity substrate
-
-
?
N-carboxybenzoyl-L-glutaminyl-glycine + hydroxylamine
hydroxamate + ?
show the reaction diagram
N-carboxybenzoyl-L-glutaminylglycine + alkylamine
?
show the reaction diagram
N-Cbz-Glu(gamma-p-nitrophenyl ester)Gly + ?
?
show the reaction diagram
-
-
-
-
?
N-Cbz-L-glutaminyl(gamma-4-nitrophenylester)glycine + alkylamine
?
show the reaction diagram
-
-
-
-
?
N-methyl-casein + dansylcadaverine
?
show the reaction diagram
N-methyl-casein + O-methyl-Gly
?
show the reaction diagram
Nalpha-benzyloxycarbonyl-L-Gln-Gly + alkylamine
?
show the reaction diagram
-
-
-
-
?
Nalpha-benzyloxycarbonyl-L-glutaminylglycine + hydroxylamine
?
show the reaction diagram
-
-
-
-
?
neuropeptide Y + 5-biotinamidopentylamine
?
show the reaction diagram
-
-
modification at residue Q34 of neuropeptide Y
-
?
NNEQVSPLTLLKLGN + glycine ethylester
?
show the reaction diagram
-
i.e. alpha2-antiplasmin peptide with modification Q2N
-
-
?
NQENVSPLTLLKLGN + glycine ethylester
?
show the reaction diagram
-
i.e. alpha2-antiplasmin peptide with modification Q4N
-
-
?
NQENVSPLTLLLLGN + glycine ethylester
?
show the reaction diagram
-
i.e. alpha2-antiplasmin peptide with modification Q4N, K12L
-
-
?
NQENVSPLTLLRLGN + glycine ethylester
?
show the reaction diagram
-
i.e. alpha2-antiplasmin peptide with modification Q4N, K12R
-
-
?
NQEQVSPLTLLKLGN + glycine ethylester
?
show the reaction diagram
-
i.e. alpha2-antiplasmin peptide
-
-
?
nucleophosmin-bound gamma-glutamine + methylamine
nucleophosmin N5-methylglutamine + NH3
show the reaction diagram
-
-
-
-
?
orexin B + 5-biotinamidopentylamine
?
show the reaction diagram
-
-
modification at residues Q8 and Q12 of orexin B
-
?
ornithine + casein
?
show the reaction diagram
-
-
-
-
?
p-nitrophenyl acetate + alanine ethylester
N-acetylalanine ethylester + p-nitrophenol
show the reaction diagram
-
-
-
?
p-nitrophenyl trimethylacetate + H2O
p-nitrophenol + trimethylacetate
show the reaction diagram
-
liver transglutaminase, ester hydrolysis in the presence of Ca2+
-
?
pollen cell-wall protein + histidine-tagged Xpr-green fluorescent protein
?
show the reaction diagram
-
-
-
-
?
pollen cell-wall protein + N',N_-dimethyl casein
?
show the reaction diagram
-
-
-
-
?
PQPQLPYPQPQLPY-NH2 + 5-biotinamidopentylamine
?
show the reaction diagram
-
-
-
-
?
protein-bound gamma-glutamine + alkylamine
protein N5-alkylglutamine + NH3
show the reaction diagram
protein-bound gamma-glutamine + methylamine
protein N5-methylglutamine + NH3
show the reaction diagram
-
-
-
-
?
protein-bound gamma-glutamine + putrescine
?
show the reaction diagram
-
-
-
-
?
putrescine + bovine muscle actin
?
show the reaction diagram
-
preferred substrate
-
-
?
putrescine + casein
?
show the reaction diagram
putrescine + fibronectin
?
show the reaction diagram
putrescine + L-glutamine
bis-(glutamyl)-putrescine
show the reaction diagram
-
-
-
-
?
putrescine + light-harvesting complex of photosystem II
?
show the reaction diagram
-
-
-
-
?
putrescine + N,N'-dimethylcasein
?
show the reaction diagram
putrescine + N,N-dimethylcasein
?
show the reaction diagram
putrescine-alginate conjugate + dimethylated casein
?
show the reaction diagram
-
putrescine (1,4-diaminobutane) covalently linked to alginate and low-methoxyl pectin, although the latter at higher concentrations, are able to act as effective acyl acceptor transglutaminase substrates in vitro using both dimethylated casein and soy flour proteins as acyl donors
-
-
?
putrescine-pectin conjugate + dimethylated casein
?
show the reaction diagram
-
putrescine (1,4-diaminobutane) covalently linked to alginate and low-methoxyl pectin, although the latter at higher concentrations, are able to act as effective acyl acceptor transglutaminase substrates in vitro using both dimethylated casein and soy flour proteins as acyl donors
-
-
?
putrescine-pectin conjugate + soy flour protein
?
show the reaction diagram
-
-
reacion produces edible films with low water vapor permeability and improved mechanical properties
-
?
QLQPFPQPQLPY + 5-biotinamidopentylamine
?
show the reaction diagram
-
-
-
-
?
spectrin alpha-bound gamma-glutamine + methylamine
spectrin alpha N5-methylglutamine + NH3
show the reaction diagram
-
-
-
-
?
spermidine + L-glutamine
bis-(glutamyl)-spermidine
show the reaction diagram
-
-
-
-
?
spermidine + light-harvesting complex of photosystem II
?
show the reaction diagram
-
-
-
-
?
spermidine + N,N-dimethylcasein
?
show the reaction diagram
-
-
-
-
?
spermine + light-harvesting complex of photosystem II
?
show the reaction diagram
-
coupling efficiency in decreasing order: spermine, spermidine, putrescine
-
-
?
Streptomyces subtilisin and TAMEP inhibitor (SSTI) + N-lauroylsarcosine
?
show the reaction diagram
sulforhodamine-beta-AQG + NK6-AP
sulforhodamine-labeled NK6-AP + ?
show the reaction diagram
NK6-AP, recombinant Escherichia coli alkaline phosphatase with a N-terminal fused acyl-acceptor substrate peptide tag MKHKGS
-
-
-
SVS I + ?
?
show the reaction diagram
major monomeric protein from mouse seminal secretions
protein is cross-linked by isoform TG4. Both SVS I and SVS III are good substrates, but less active than SVS II
-
?
SVS II + ?
?
show the reaction diagram
major monomeric protein from mouse seminal secretions
protein is cross-linked by isoform TG4. Both SVS I and SVS III are good substrates, but less active than SVS II
-
?
SVS III + ?
?
show the reaction diagram
major monomeric protein from mouse seminal secretions
protein is cross-linked by isoform TG4. Both SVS I and SVS III are good substrates, but less active than SVS II
-
?
thermolysin(205-316) + carbobenzoxy-L-glutaminylglycine
?
show the reaction diagram
-
-
-
-
?
thermolysin(205-316) + dansylcadaverine
?
show the reaction diagram
-
-
-
-
?
thylakoid protein + putrescine
?
show the reaction diagram
-
the incorporation of putrescine by the recombinant protein are 100fold greater using light-grown than dark-grown thylakoid protein extracts
-
-
?
vimentin + 5-(biotinamido)pentylamine
?
show the reaction diagram
-
transglutaminase 5
-
-
?
vimentin + ?
?
show the reaction diagram
-
-
formation of water-insoluble dimers or polymers
-
?
vimentin-bound gamma-glutamine + methylamine
vimentin N5-methylglutamine + NH3
show the reaction diagram
-
-
-
-
?
YELQRPYHSELP + biotinylated cadaverine
?
show the reaction diagram
-
preferred substrate, acitve even in the peptide form
-
-
?
YELQRPYHSELP-glutathione-S-transferase + biotinylated cadaverine
?
show the reaction diagram
-
preferred substrate
-
-
?
Z-Gln-Gly + H2O
?
show the reaction diagram
Z-Gln-Gly + O-methyl-Gly
?
show the reaction diagram
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
actin + ?
?
show the reaction diagram
-
-
-
-
?
CBP40 + ?
?
show the reaction diagram
-
a 40 kDa Ca2+-binding protein accumulating most significantly around injured areas
-
-
?
Cbz-L-Gln-Gly + alkylamine
?
show the reaction diagram
-
-
-
-
?
fibrinogen-bound gamma-glutamine + 5-(biotinamido)pentylamine
fibrinogen N5-(biotinamido)pentyl-glutamine + NH3
show the reaction diagram
-
-
-
-
?
fibronectin-bound gamma-glutamine + alkylamine
fibronectin N5-alkylglutamine + NH3
show the reaction diagram
Q7M0F8
-
-
-
?
leishmanolysin + alkylamine
?
show the reaction diagram
-
-
-
-
?
myo-inositol-1-phosphate synthase + alkylamine
?
show the reaction diagram
-
-
-
-
?
N,N-dimethylated casein-bound gamma-glutamine + dansyl-labeled amine nucleophile
?
show the reaction diagram
-
-
-
-
?
N,N-dimethylcasein + putrescine
?
show the reaction diagram
-
-
-
-
?
N-acetyl-PNPQLPF + alkylamine
?
show the reaction diagram
-
-
-
-
?
N-carbobenzoxy-L-glutaminylglycine + NH2OH
L-glutamic acid-gamma-monohydroxamate + ?
show the reaction diagram
-
specific high-affinity substrate
-
-
?
N-carboxybenzoyl-L-glutaminylglycine + alkylamine
?
show the reaction diagram
N-Cbz-L-glutaminyl(gamma-4-nitrophenylester)glycine + alkylamine
?
show the reaction diagram
-
-
-
-
?
Nalpha-benzyloxycarbonyl-L-glutaminylglycine + hydroxylamine
?
show the reaction diagram
-
-
-
-
?
pollen cell-wall protein + histidine-tagged Xpr-green fluorescent protein
?
show the reaction diagram
-
-
-
-
?
pollen cell-wall protein + N',N_-dimethyl casein
?
show the reaction diagram
-
-
-
-
?
protein-bound gamma-glutamine + alkylamine
protein N5-alkylglutamine + NH3
show the reaction diagram
protein-bound gamma-glutamine + putrescine
?
show the reaction diagram
-
-
-
-
?
thylakoid protein + putrescine
?
show the reaction diagram
-
the incorporation of putrescine by the recombinant protein are 100fold greater using light-grown than dark-grown thylakoid protein extracts
-
-
?
additional information
?
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Ba2+
-
activation, can replace Ca2+ to a lesser extent
KCl
-
about 8fold activation, maximum activation at 0.6-0.8 M
La3+
-
requirement, 0.01-0.1 mM
LiCl
-
about 6fold activation, maximum activation at 0.6-0.8 M
NaCl
-
about 10fold activation, maximum activation at 0.6-0.8 M
Zn2+
-
activation, 24.6% as effective as Ca2+
additional information
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(1Z)-2-{[3-(3-fluorophenyl)-5-(2-methoxyphenyl)-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-2-yl]sulfanyl}ethanehydrazonic acid
-
-
(2E)-3-(4-nitrophenyl)-1-(pyridin-3-yl)prop-2-en-1-one
-
reversible, competitive with the acyl donor substrate
(3E)-1-benzyl-4-chloro-3-[2-oxo-2-(pyridin-3-yl)ethylidene]-1,3-dihydro-2H-indol-2-one
-
-
(3E)-3-(2-oxopropylidene)-6-(trifluoromethoxy)-1,3-dihydro-2H-indol-2-one
-
-
(3E)-3-[2-(3-aminophenyl)-2-oxoethylidene]-4-chloro-1,3-dihydro-2H-indol-2-one
-
-
(3E)-3-[2-(4-aminophenyl)-2-oxoethylidene]-4-chloro-1,3-dihydro-2H-indol-2-one
-
-
(3E)-3-[2-(5-bromopyridin-3-yl)-2-oxoethylidene]-4-chloro-1,3-dihydro-2H-indol-2-one
-
-
(3E)-3-[2-oxo-2-(pyridin-3-yl)ethylidene]-1,3-dihydro-2H-indol-2-one
-
-
(3E)-4-bromo-3-[2-oxo-2-(pyridin-3-yl)ethylidene]-1,3-dihydro-2H-indol-2-one
-
-
(3E)-4-chloro-1-(2-methylpropyl)-3-[2-oxo-2-(pyridin-3-yl)ethylidene]-1,3-dihydro-2H-indol-2-one
-
-
(3E)-4-chloro-1-(cyclohexylmethyl)-3-[2-oxo-2-(pyridin-3-yl)ethylidene]-1,3-dihydro-2H-indol-2-one
-
-
(3E)-4-chloro-1-methyl-3-[2-oxo-2-(pyridin-3-yl)ethylidene]-1,3-dihydro-2H-indol-2-one
-
-
(3E)-4-chloro-3-(2-oxo-2-phenylethylidene)-1,3-dihydro-2H-indol-2-one
-
-
(3E)-4-chloro-3-(2-oxopropylidene)-1,3-dihydro-2H-indol-2-one
-
-
(3E)-4-chloro-3-[2-(2-methoxyphenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
-
-
(3E)-4-chloro-3-[2-(3-chlorophenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
-
-
(3E)-4-chloro-3-[2-(3-methoxyphenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
-
-
(3E)-4-chloro-3-[2-(4-chlorophenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
-
-
(3E)-4-chloro-3-[2-(4-methoxyphenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
-
-
(3E)-4-chloro-3-[2-(6-methoxypyridin-3-yl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
-
-
(3E)-4-chloro-3-[2-oxo-2-(pyridin-2-yl)ethylidene]-1,3-dihydro-2H-indol-2-one
-
-
(3E)-4-chloro-3-[2-oxo-2-(pyridin-3-yl)ethylidene]-1,3-dihydro-2H-indol-2-one
-
-
(3E)-4-chloro-3-[2-oxo-2-(pyridin-3-yl)ethylidene]-1-(2-phenylethyl)-1,3-dihydro-2H-indol-2-one
-
-
(3E)-4-chloro-3-[2-oxo-2-(pyridin-3-yl)ethylidene]-1-(3-phenylpropyl)-1,3-dihydro-2H-indol-2-one
-
-
(3E)-4-chloro-3-[2-oxo-2-(pyridin-3-yl)ethylidene]-1-(propan-2-yl)-1,3-dihydro-2H-indol-2-one
-
-
(3E)-4-chloro-3-[2-oxo-2-(pyridin-3-yl)ethylidene]-1-phenyl-1,3-dihydro-2H-indol-2-one
-
-
(3E)-4-chloro-3-[2-oxo-2-(pyridin-4-yl)ethylidene]-1,3-dihydro-2H-indol-2-one
-
-
(3E)-5-bromo-3-[2-oxo-2-(pyridin-3-yl)ethylidene]-1,3-dihydro-2H-indol-2-one
-
-
(3E)-5-chloro-3-(2-oxopropylidene)-1,3-dihydro-2H-indol-2-one
-
-
(3E)-5-chloro-3-[2-oxo-2-(pyridin-3-yl)ethylidene]-1,3-dihydro-2H-indol-2-one
-
-
(3E)-5-methyl-3-[2-oxo-2-(pyridin-3-yl)ethylidene]-1,3-dihydro-2H-indol-2-one
-
-
(3E)-5-nitro-3-[2-oxo-2-(pyridin-3-yl)ethylidene]-1,3-dihydro-2H-indol-2-one
-
-
(3E)-6-bromo-3-[2-oxo-2-(pyridin-3-yl)ethylidene]-1,3-dihydro-2H-indol-2-one
-
-
(3E)-6-chloro-3-[2-oxo-2-(pyridin-3-yl)ethylidene]-1,3-dihydro-2H-indol-2-one
-
-
(3E)-6-fluoro-3-(2-oxopropylidene)-1,3-dihydro-2H-indol-2-one
-
-
(3E)-7-bromo-3-[2-oxo-2-(pyridin-3-yl)ethylidene]-1,3-dihydro-2H-indol-2-one
-
-
(3E)-7-chloro-3-(2-oxopropylidene)-1,3-dihydro-2H-indol-2-one
-
-
(3E)-7-chloro-3-[2-oxo-2-(pyridin-3-yl)ethylidene]-1,3-dihydro-2H-indol-2-one
-
-
(4R)-1-[(benzyloxy)carbonyl]-4-hydroxy-L-prolyl-6-(dimethylsulfonio)-5-oxo-L-norleucine bromide
-
-
(5-bromothiophen-2-yl)(4-methyl-1H-pyrazol-1-yl)methanone
-
-
(E)-1-(1-(2-nitrobenzyl)-1H-1,2,3-triazol-4-yl)-3-(4-nitrophenyl)prop-2-en-1-one
-
(E)-1-(1-(3-nitrobenzyl)-1H-1,2,3-triazol-4-yl)-3-(4-nitrophenyl)prop-2-en-1-one
-
(E)-1-(1-(4-nitrobenzyl)-1H-1,2,3-triazol-4-yl)-3-(4-nitrophenyl)prop-2-en-1-one
-
(E)-1-(1-(cyclohexylmethyl)-1H-1,2,3-triazol-4-yl)-3-(4-nitrophenyl)prop-2-en-1-one
-
(E)-1-(1-benzyl-1H-1,2,3-triazol-4-yl)-3-(4-nitrophenyl)prop-2-en-1-one
-
(NH4)2SO4
Nemipterus sp.
-
-
(S)-N-(((S)-3-bromo-4,5-dihydroisoxazol-5-yl)methyl)-2-(1-(dimethylamino)naphthalene-5-sulfonamido)-3-(1H-indol-3-yl)propanamide
-
the majority of cellular TG2 cannot be inhibited in intact cells. The inhibitor potently inhibits cell lysate TG2 activity in the presence of calcium
1,1'-methanediylbis(1H-indole-2,3-dione)
-
-
1,1'-[(2,5-dimethylbenzene-1,4-diyl)dimethanediyl]bis(1H-indole-2,3-dione)
-
-
1,1'-[(4,6-dimethylbenzene-1,3-diyl)dimethanediyl]bis(1H-indole-2,3-dione)
-
-
1,3-dimethyl-2-[(2-oxopropyl)thio]-1H-imidazol-3-ium
-
-
1,3-dimethyl-2-[(2-oxopropyl)thio]imidazolium
-
pan-transglutaminase inhibition inhibits terminal differentiation of keratinocytes, leading to a hyperproliferative epidermis with parakeratosis and enhanced expression of involucrin and cytokeratins 6 and 16. Expression of the differentiation-associated cytokeratin, cytokeratin 10, is reduced. Basement membrane integrity is also lost as a result of transglutaminase inhibition
1-(1-benzothiophen-2-yl)-3-[benzyl(tert-butyl)amino]propan-1-one
-
-
1-(furan-2-yl)-3-[(2-hydroxyethyl)(propan-2-yl)amino]propan-1-one
-
-
1-acetyl-L-prolyl-6-imino-5-oxo-L-norleucyl-L-leucyl-L-prolyl-L-phenylalaninamide
-
-
1-ethyl-3-(4-methoxyphenyl)-6-methylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione
-
-
1-[(2E)-3-(4-nitrophenyl)prop-2-enoyl]-3H-[1,2,3]triazolo[4,5-b]pyridin-1-ium-3-olate
-
reversible, competitive with the acyl donor substrate
-
1-[(benzyloxy)carbonyl]-L-prolyl-6-(dimethylsulfonio)-5-oxo-L-norleucine bromide
-
-
2,3-dibromonaphthoquinone
-
0.015 mM, 41.5% inhibition
2-([3-(2-chlorophenyl)-4-oxo-5-phenyl-3,4-dihydrothieno[2,3-d]pyrimidin-2-yl]thio)acetohydrazide
-
50% inhibition at 0.0015 mM, standard format
2-([3-(2-fluorophenyl)-4-oxo-5-phenyl-3,4-dihydrothieno[2,3-d]pyrimidin-2-yl]thio)acetohydrazide
2-([3-(2-methoxyphenyl)-4-oxo-5-phenyl-3,4-dihydrothieno[2,3-d]pyrimidin-2-yl]thio)acetohydrazide
-
50% inhibition at 0.00082 mM, standard format, at 0.00047 mM, full progress curve
2-([3-(3-chlorophenyl)-4-oxo-5-phenyl-3,4-dihydrothieno[2,3-d]pyrimidin-2-yl]thio)acetohydrazide
-
50% inhibition at 0.0018 mM, standard format
2-([3-(3-fluorophenyl)-4-oxo-3,4,5,6,7,8-hexahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-2-yl]thio)acetohydrazide
-
-
2-([3-(3-fluorophenyl)-4-oxo-3,4,5,6,7,8-hexahydro[1]benzothieno[2,3-d]pyrimidin-2-yl]thio)acetohydrazide
-
50% inhibition at 0.00045 mM, full progress curve
2-([3-(3-fluorophenyl)-4-oxo-5-phenyl-3,4-dihydrothieno[2,3-d]pyrimidin-2-yl]thio)acetohydrazide
2-([3-(3-fluorophenyl)-4-oxo-6-phenyl-3,4-dihydroquinazolin-2-yl]thio)acetohydrazide
-
-
2-([3-(3-fluorophenyl)-5-(2-hydroxyphenyl)-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-2-yl]thio)acetohydrazide
-
50% inhibition at 0.0008 mM, standard format, at 0.00025 mM, full progress curve
2-([3-(3-fluorophenyl)-5-(2-methoxyphenyl)-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-2-yl]thio)acetohydrazide
-
-
2-([3-(3-fluorophenyl)-5-(3-diethylaminopropoxyphenyl)-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-2-yl]thio)acetohydrazide
-
-
2-([3-(3-fluorophenyl)-5-(3-methoxyphenyl)-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-2-yl]thio)acetohydrazide
-
50% inhibition at 0.0014 mM, standard format
2-([3-(3-fluorophenyl)-5-methyl-4-oxo-3,4,5,6,7,8-hexahydro[1]benzothieno[2,3-d]pyrimidin-2-yl]thio)acetohydrazide
-
50% inhibition at 0.0002 mM, full progress curve
2-([3-(3-fluorophenyl)-5-phenyl-4-oxo-3,4,5,6,7,8-hexahydro[1]benzothieno[2,3-d]pyrimidin-2-yl]thio)acetohydrazide
-
50% inhibition at 0.00093 mM, standard format, at 0.00071 mM, full progress curve
2-([3-(3-fluorophenyl)-7-methyl-4-oxo-3,4,5,6,7,8-hexahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-2-yl]thio)acetohydrazide
-
50% inhibition at 0.00053 mM, full progress curve
2-([3-(3-methoxyphenyl)-4-oxo-5-phenyl-3,4-dihydrothieno[2,3-d]pyrimidin-2-yl]thio)acetohydrazide
-
50% inhibition at 0.0021 mM, standard format
2-([3-(4-chlorophenyl)-4-oxo-5-phenyl-3,4-dihydrothieno[2,3-d]pyrimidin-2-yl]thio)acetohydrazide
-
50% inhibition at 0.0005 mM, standard format, at 0.00016 mM, full progress curve
2-([3-(4-methoxyphenyl)-4-oxo-5-phenyl-3,4-dihydrothieno[2,3-d]pyrimidin-2-yl]thio)acetohydrazide
-
50% inhibition at 0.0018 mM, standard format
2-([5-(4-fluorophenyl)-4-oxo-3-phenyl-3,4-dihydrothieno[2,3-d]pyrimidin-2-yl]thio)acetohydrazide
-
50% inhibition at 0.0008 mM, standard format, at 0.00029 mM, full progress curve
2-aminonaphthoquinone
-
0.015 mM, 33.4% inhibition
2-Aminophenol
-
-
2-Aminothiophenol
-
-
2-bromo-3-hydroxynaphthoquinone
-
0.015 mM, 35.4% inhibition
2-Iodoacetamide
-
-
2-[(2-hydrazinoethyl)thio]-3,5-diphenylthieno[2,3-d]pyrimidin-4(3H)-one
-
i.e. LDN-27219, reversible, slow-binding inhibitor that binds at the enzyme’s GTP site or a site that regulates binding of GTP
2-[(3-amino-2-oxopropyl)thio]-3-(3-fluorophenyl)-5-phenylthieno[2,3-d]pyrimidin-4(3H)-one
-
50% inhibition at 0.0053 mM, standard format
2-[(3-benzyl-4-oxo-5-phenyl-3,4-dihydrothieno[2,3-d]pyrimidin-2-yl)thio]acetohydrazide
-
50% inhibition at 0.0012 mM, standard format, at 0.00048 mM, full progress curve
2-[(3-methyl-4-oxo-5-phenyl-3,4-dihydrothieno[2,3-d]pyrimidin-2-yl)thio]acetohydrazide
-
50% inhibition at 0.0023 mM, standard format
2-[(3E)-4-chloro-2-oxo-3-[2-oxo-2-(pyridin-3-yl)ethylidene]-2,3-dihydro-1H-indol-1-yl]-N,N-dimethylacetamide
-
-
2-[(4-oxo-3,5-diphenyl-3,4-dihydrothieno[2,3-d]pyrimidin-2-yl)amino]acetohydrazide
-
50% inhibition at 0.0037 mM, full progress curve
2-[(4-oxo-3,5-diphenyl-3,4-dihydrothieno[2,3-d]pyrimidin-2-yl)oxy]acetohydrazide
-
50% inhibition at 0.0045 mM, standard format
2-[(4-oxo-3,5-diphenyl-3,4-dihydrothieno[2,3-d]pyrimidin-2-yl)thio]acetohydrazide
-
50% inhibition at 0.0008 mM, standard format, at 0.00025 mM, full progress curve
2-[(4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)thio]acetohydrazide
-
-
2-[(4-oxo-3-phenyl-3,4-dihydrothieno[2,3-d]pyrimidin-2-yl)thio]acetohydrazide
-
-
2-[(4-oxo-5-phenyl-3-pyridin-3-yl-3,4-dihydrothieno[2,3-d]pyrimidin-2-yl)thio]acetohydrazide
-
50% inhibition at 0.002 mM, standard format
2-[(6-methyl-4-oxo-3,5-diphenyl-3,4-dihydrothieno[2,3-d]pyrimidin-2-yl)thio]acetohydrazide
-
50% inhibition at 0.0015 mM, standard format, at 0.00016 mM, full progress curve
2-[[3-(2-fluorophenyl)-4-oxo-5-phenyl-3,4-dihydrothieno[2,3-d]pyrimidin-2-yl]thio]acetohydrazide
-
-
2-[[3-(3-fluorophenyl)-4-oxo-3,4,5,6,7,8-hexahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-2-yl]thio]acetohydrazide
-
-
2-[[3-(3-fluorophenyl)-4-oxo-5-phenyl-3,4,5,6,7,8-hexahydro[1]benzothieno[2,3-d]pyrimidin-2-yl]sulfanyl]acetohydrazide
-
-
2-[[3-(3-fluorophenyl)-4-oxo-5-phenyl-3,4-dihydrothieno[2,3-d]pyrimidin-2-yl]thio]acetohydrazide
-
-
2-[[3-(3-fluorophenyl)-4-oxo-6-phenyl-3,4-dihydroquinazolin-2-yl]thio]acetohydrazide
-
-
2-[[5-benzyl-3-(3-fluorophenyl)-4-oxo-3,4,5,6,7,8-hexahydro[1]benzothieno[2,3-d]pyrimidin-2-yl]sulfanyl]acetohydrazide
-
-
2-[[5-[2-[3-(diethylamino)propoxy]phenyl]-3-(3-fluorophenyl)-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-2-yl]sulfanyl]acetohydrazide
-
-
3-(3-methyl-3H-diaziren-3-yl)-N-[4-[(1E)-3-oxo-3-(pyridin-3-yl)prop-1-en-1-yl]phenyl]propanamide
-
reversible inhibitor and photolabel. In labeling experiments, specific labeling of residue C230
3-(4-acryloylaminobenzenesulfonylamino)-(R)-pyrrolidine-1-carboxylic acid benzyl ester
-
-
3-(4-acryloylaminobenzenesulfonylamino)-(S)-pyrrolidine-1-carboxylic acid benzyl ester
-
-
3-Aminophenol
-
-
3-aminothiophenol
-
-
3-[(2E)-3-(3-nitrophenyl)prop-2-enoyl]-1H-benzotriazol-3-ium-1-olate
-
reversible, competitive with the acyl donor substrate
3-[(6-methyl-4-oxo-3,5-diphenyl-3,4-dihydrothieno[2,3-d]pyrimidin-2-yl)thio]propanohydrazide
-
50% inhibition at 0.0013 mM, standard format
3-[benzyl(ethyl)amino]-1-(5-chlorothiophen-2-yl)propan-1-one
-
-
3-[benzyl(propan-2-yl)amino]-1-(5-bromothiophen-2-yl)propan-1-one
-
-
3-[benzyl(propan-2-yl)amino]-1-(5-chlorothiophen-2-yl)propan-1-one
-
-
3-[benzyl(tert-butyl)amino]-1-(4-nitrophenyl)propan-1-one
-
-
3-[benzyl(tert-butyl)amino]-1-(5-bromothiophen-2-yl)propan-1-one
3-[benzyl(tert-butyl)amino]-1-(5-chlorothiophen-2-yl)propan-1-one
-
-
3-[benzyl(tert-butyl)amino]-1-(thiophen-2-yl)propan-1-one
-
-
3-[bis(2-hydroxyethyl)amino]-1-(furan-2-yl)propan-1-one
-
-
4-(2-acryloylaminopyrimidine-5-sulfonyl)piperazine-1-carboxylic acid benzyl ester
-
-
4-(2-acryloylaminopyrimidine-5-sulfonyl)piperazine-1-carboxylic acid tert-butyl ester
-
-
4-(3-acryloylaminobenzenesulfonyl)piperazine-1-carboxylicacid benzyl ester
-
-
4-(4-acryloylamino-2-chlorobenzenesulfonyl)piperazine-1-carboxylic acid tert-butyl ester
-
-
4-(4-acryloylamino-2-fluorobenzenesulfonyl)piperazine-1-carboxylic acid tert-butyl ester
-
-
4-(4-acryloylamino-2-methoxybenzenesulfonyl)piperazine-1-carboxylic acid tert-butyl ester
-
-
4-(4-acryloylamino-2-methylbenzenesulfonyl)piperazine-1-carboxylic acid tert-butyl ester
-
-
4-(4-acryloylamino-2-trifluoromethylbenzenesulfonyl)-piperazine-1-carboxylic acid benzyl ester
-
-
4-(4-acryloylamino-3-fluorobenzenesulfonyl)piperazine-1-carboxylic acid benzyl ester
-
-
4-(4-acryloylaminobenzenesulfonyl)piperazine-1-carboxylic acid 2-chlorobenzyl ester
-
-
4-(4-acryloylaminobenzenesulfonyl)piperazine-1-carboxylic acid 2-methylbenzyl ester
-
-
4-(4-acryloylaminobenzenesulfonyl)piperazine-1-carboxylic acid 2-trifluoromethylbenzyl ester
-
-
4-(4-acryloylaminobenzenesulfonyl)piperazine-1-carboxylic acid 3,5-difluorobenzyl ester
-
-
4-(4-acryloylaminobenzenesulfonyl)piperazine-1-carboxylic acid benzyl ester
-
-
4-(4-acryloylaminobenzenesulfonyl)piperazine-1-carboxylic acid cyclopentyl ester
-
-
4-(4-acryloylaminobenzenesulfonyl)piperazine-1-carboxylic acid methyl ester
-
-
4-(4-acryloylaminobenzenesulfonyl)piperazine-1-carboxylic acid naphthalen-1-ylmethyl ester
-
-
4-(4-acryloylaminobenzenesulfonyl)piperazine-1-carboxylic acid naphthalen-2-ylmethyl ester
-
-
4-(4-acryloylaminobenzenesulfonyl)piperazine-1-carboxylic acid tert-butyl ester
-
-
4-(4-acryloylaminobenzenesulfonyl)piperazine-1-carboxylicacid 2,3-difluorobenzyl ester
-
-
4-(4-acryloylaminobenzenesulfonyl)piperazine-1-carboxylicacid 4-fluorobenzyl ester
-
-
4-(4-acryloylaminobenzenesulfonyl)piperazine-1-carboxylicacid ethyl ester
-
-
4-(4-acryloylaminobenzenesulfonyl)[1,4]diazepane-1-carboxylicacid benzyl ester
-
-
4-(4-acryloylaminobenzenesulfonylamino)piperidine-1-carboxylic acid benzyl ester
-
-
4-(4-but-2-enoylaminobenzenesulfonyl)piperazine-1-carboxylic acid tert-butyl ester
-
-
4-(4-cyanobenzenesulfonyl)piperazine-1-carboxylic acid tert-butyl ester
-
-
4-(6-acryloylaminopyridine-3-sulfonyl)piperazine-1-carboxylic acid benzyl ester
-
-
4-(6-acryloylaminopyridine-3-sulfonyl)piperazine-1-carboxylic acid tert-butyl ester
-
-
4-Aminophenol
-
-
4-aminothiophenol
-
-
4-[(4-acryloylaminobenzenesulfonylamino)methyl]-piperidine-1-carboxylic acid benzyl ester
-
-
4-[4-(1-oxobut-2-ynylamino)benzenesulfonyl]piperazine-1-carboxylic acid tert-butyl ester
-
-
4-[4-(2-cyanoacetylamino)benzenesulfonyl]piperazine-1-carboxylic acid tert-butyl ester
-
-
4-[4-(2-ethoxycarbonylvinyl)benzenesulfonyl]piperazine-1-carboxylic acid benzyl ester
-
-
4-[4-(2-fluoroacryloylamino)benzenesulfonyl]piperazine-1-carboxylic acid tert-butyl ester
-
-
4-[4-(2-methylacryloylamino)benzenesulfonyl]piperazine-1-carboxylic acid tert-butyl ester
-
-
4-[4-(2-methylbut-2-enoylamino)benzenesulfonyl]-piperazine-1-carboxylic acid tert-butyl ester
-
-
4-[4-(2-oxopropionylamino)benzenesulfonyl]piperazine-1-carboxylic acid tert-butyl ester
-
-
4-[4-(3-(E)-chloroacryloylamino)benzenesulfonyl]-piperazine-1-carboxylic acid tert-butyl ester
-
-
4-[4-(3-(Z)-chloroacryloylamino)benzenesulfonyl]-piperazine-1-carboxylic acid tert-butyl ester
-
-
4-[4-(3-cyanomethylureido)benzenesulfonyl]piperazine-1-carboxylic acid tert-butyl ester
-
-
4-[4-(3-diazo-2-oxopropyl)benzenesulfonyl]piperazine-1-carboxylic acid benzyl ester
-
-
4-[4-(3-ethoxycarbonylallyl)benzenesulfonyl]piperazine-1-carboxylic acid benzyl ester
-
-
4-[4-(4,4,4-trifluoro-3-methylbut-2-enoylamino)-benzenesulfonyl]piperazine-1-carboxylic acid tert-butyl ester
-
-
4-[4-(4,4,4-trifluorobut-2-enoylamino)benzenesulfonyl]-piperazine-1-carboxylic acid tert-butyl ester
-
-
4-[4-(4-diazo-3-oxobutyl)benzenesulfonyl]piperazine-1-carboxylic acid benzyl ester
-
-
4-[4-(acryloylmethyl-amino)benzenesulfonyl]piperazine-1-carboxylic acid tert-butyl ester
-
-
4-[4-(cyanomethylcarbamoyl)benzenesulfonyl]piperazine-1-carboxylic acid tert-butyl ester
-
-
4-[4-(ethoxycarbonylmethylamino)benzenesulfonyl]-piperazine-1-carboxylic acid tert-butyl ester
-
-
4-[4-acryloylamino-3-(isobutylmethylamino)-benzenesulfonyl]piperazine-1-carboxylic acid benzyl ester
-
-
5,5'-dithiobis (2-nitrobenzoic acid)
-
-
5,5'-dithiobis(2-nitrobenzoic acid)
5,5'-methanediylbis(1H-indole-2,3-dione)
-
-
5,5'-oxybis(1H-indole-2,3-dione)
-
-
5-(4-acryloylaminobenzenesulfonyl)-2,5-diazabicyclo-[2.2.1]heptane-2-carboxylic acid tert-butyl ester
-
-
5-(4-acryloylaminobenzenesulfonyl)hexahydropyrrolo[3,4-c]pyrrole-2-carboxylic acid benzyl ester
-
-
5-(biotinamido)pentylamine
-
-
5-hydroxynaphthoquinone
-
0.015 mM, 46.1% inhibition
6,6'-oxybis(1H-indole-2,3-dione)
-
-
Ac-P(6-diazo-5-oxo-L-norleucine)LPF-NH2
-
high-affinity irreversible inhibitor of TG2. The inhibitor stabilizes TG2 in an extended conformation that is dramatically different from earlier transglutaminase structures. The active site is exposed, revealing that catalysis takes place in a tunnel, bridged by two tryptophan residues that separate acyl-donor from acyl-acceptor and stabilize the tetrahedral reaction intermediates
acetonitrile
-
48% residual activity at 5% (v/v)
alpha-difluoromethylornithine
-
2.6 mM, 50% inhibition of putrescine transfer to casein, suicide substrate, irreversible, competitive to putrescine or fibrinonectin
AMP
-
weak inhibition of liver transglutaminase
Ba2+
-
10 mM, complete inhibition
benzyl 3-(3-fluorophenyl)-2-[(2-hydrazino-2-oxoethyl)sulfanyl]-4-oxo-3,5,6,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidine-7(4H)-carboxylate
-
-
benzyl [(1R)-2-[[(3-bromo-4,5-dihydroisoxazol-5-yl)methyl]amino]-1-(methylamino)-2-oxoethyl]carbamate
-
irreversible
beta-mercaptoethanolamine
-
mechanism of inhibition, mercapto group significantly influences substrate behaviour
beta-selenoethanolamine
-
-
Boc-DON-Gln-Ile-Val-OMe
-
-
BOC-DON-QIV-OMe
-
0.1 mM and 1 mM for normal skin and keloid scar, respectively
butanolamine
-
-
Ca2+
-
above 10 mM
cadaverine
Ce3+
-
not reversible by Ca2+
chlorpromazine
Co2+
Nemipterus sp.
-
-
CP30a
-
reversible inhibitor
CP4d
-
reversible inhibitor
cystamine
cystamine dihydrochloride
-
1 mM and 10 mM for normal skin and keloid scar, respectively
cysteamine
-
50% inhibition at 0.178 mM
cysteine
-
85% inhibition
Dansylcadaverine
diethyl dicarbonate
-
not without Ca2+
dithiothreitol
-
1.5 mM, 42% inhibition, 16.5 mM, 40% inhibition
DMF
-
90% residual activity at 2.5 and 5% (v/v)
ERW1041E
-
-
ethanolamine
-
-
ethenesulfonic acid (4-bromophenyl)amide
-
-
ethyl [(3E)-4-chloro-2-oxo-3-[2-oxo-2-(pyridin-3-yl)ethylidene]-2,3-dihydro-1H-indol-1-yl]acetate
-
-
fluorenylmethyl [4-[(1E)-3-(1H-benzotriazol-1-yl)-3-oxoprop-1-en-1-yl]phenyl]carbamate
-
reversible, competitive with the acyl donor substrate
Gd3+
-
not reversible by Ca2+
glucosamine
-
the TGase 2 inhibitor, might be an attractive novel target for treatment of malignant cancers
GMP
-
at low levels of Ca2
GSSG
-
reversible inactivation, activity can be restored by treatment with dithiothreitol
GTP-gamma-S
HgCl2
-
5 mM, 96% inhibition in the presence of 10 mM Ca2+
hydroxylamine
-
100 mM, complete inhibition
Hydroxymercuribenzoate
-
99% inactivation
-
indirubin
-
-
iodoacetamide
iodoacetic acid
-
10 mM, complete inhibition
isatin
-
weak, reversible inhibitor
isoindigotin
-
-
K+
-
1 mM, 41% inhibition
KCC009
La3+
-
not reversible by Ca2+
LDN-27219
Li+
-
10 mM, complete inhibition
lysine
-
1 mM, 43% inhibition of DEAE-unabsorbed transglutaminase, 90% inhibition of DEAE-absorbed transglutaminase
menadione
-
0.015 mM, 97% inhibition
methyl 3-([(3E)-4-chloro-2-oxo-3-[2-oxo-2-(pyridin-3-yl)ethylidene]-2,3-dihydro-1H-indol-1-yl]methyl)benzoate
-
-
methyl 4-([(3E)-4-chloro-2-oxo-3-[2-oxo-2-(pyridin-3-yl)ethylidene]-2,3-dihydro-1H-indol-1-yl]methyl)benzoate
-
-
methyl 4-[(1E)-3-(1H-benzotriazol-1-yl)-3-oxoprop-1-en-1-yl]benzoate
-
reversible, competitive with the acyl donor substrate
methyl ketone
-
-
methyl N-[(benzyloxy)carbonyl]-L-phenylalanyl-6-(dimethylsulfonio)-5-oxo-L-norleucinate bromide
-
-
methylamine
MgCl2
-
5 mM, 88% inhibition, 30% inhibition in the presence of 10 mM Ca2+
monodansyl cadaverine
-
-
Monodansylcadaverine
monoiodoacetate
Monoiodoacetic acid
Nemipterus sp.
-
-
N-(2-bromophenyl)acrylamide
-
-
N-(3-bromophenyl)acrylamide
-
-
N-(3-methyl-1,2,4-thiadiazol-5-yl)-N2-(phenoxycarbonyl)-L-glutaminylglycine
-
irreversible, ratio kinact to Ki 0.33 micromol per min
N-(4-bromobenzyl)acrylamide
-
-
N-(4-bromophenyl)acrylamide
-
-
N-(4-bromophenyl)propionamide
-
-
N-(4-fluorophenyl)acrylamide
-
-
N-(4-[4-[2-(2-phenoxyphenyl)acetyl]piperazine-1-sulfonyl]-phenyl)acrylamide
-
-
N-(4-[4-[2-(3-phenoxyphenyl)acetyl]piperazine-1-sulfonyl]-phenyl)acrylamide
-
-
N-(4-[4-[2-(4-phenoxyphenyl)acetyl]piperazine-1-sulfonyl]- phenyl)acrylamide
-
-
N-(4-[4-[2-(4-phenoxyphenyl)acetyl]piperazine-1-sulfonyl]-phenyl)acrylamide
-
-
N-(phenylcarbonyl)-L-phenylalanyl-6-(dimethylsulfonio)-5-oxo-L-norleucine bromide
-
-
N-(tert-butoxycarbonyl)-L-phenylalanyl-6-(dimethylsulfonio)-5-oxo-L-norleucine bromide
-
-
N-acetyl-P(6-diazo-5-oxo-L-norleucine)LPF-NH2
-
active-site inhibitor
N-benzyloxycarbonyl-L-glutaminyl-6-(dimethylsulfonio)-5-oxo-L-norleucine
-
pan-transglutaminase inhibition inhibits terminal differentiation of keratinocytes, leading to a hyperproliferative epidermis with parakeratosis and enhanced expression of involucrin and cytokeratins 6 and 16. Expression of the differentiation-associated cytokeratin, cytokeratin 10, is reduced. Basement membrane integrity is also lost as a result of transglutaminase inhibition
N-carbobenzyloxy-L-phenylalanine 2-(acrylamido)ethylamide
-
-
N-carbobenzyloxy-L-phenylalanine 4-(acrylamido)butylamide
-
-
N-carbobenzyloxy-L-phenylalanine 4-(chloroacetylamido)butylamide
-
-
N-carbobenzyloxy-L-phenylalanine 6-(acrylamido)hexylamide
-
-
N-carbobenzyloxy-L-phenylalanine 6-(chloroacetylamido)hexylamide
-
-
N-carbobenzyloxy-L-phenylalanine 8-(acrylamido)octylamide
-
-
N-ethylmaleimide
N-iodoacetyl-N'-(5-sulfo-1-naphthyl)ethylenediamine
-
0.01 mM, 91% and 92% inhibition of chondrosarcoma transglutaminases B and C respectively
N-phenylacrylamide
-
-
N-[(2-phenylethoxy)carbonyl]-L-phenylalanyl-6-(dimethylsulfonio)-5-oxo-L-norleucine bromide
-
-
N-[(2S)-4-[(3-methoxy-1,2,4-thiadiazol-5-yl)amino]-2-[(phenoxycarbonyl)amino]butanoyl]glycine
-
irreversible, ratio kinact to Ki 0.71 micromol per min
N-[(3-bromo-4,5-dihydroisoxazol-5-yl)methyl]-5-fluoro-Na-[(quinolin-3-ylmethoxy)carbonyl]-L-tryptophanamide
-
-
N-[(3-bromo-4,5-dihydroisoxazol-5-yl)methyl]-5-fluoro-Na-[(quinolin-3-ylmethoxy)carbonyl]tryptophanamide
-
-
N-[(3-bromo-4,5-dihydroisoxazol-5-yl)methyl]-Nalpha-[(2-phenylethoxy)carbonyl]-L-tyrosinamide
-
irreversible
N-[(3-bromo-4,5-dihydroisoxazol-5-yl)methyl]-Nalpha-[(naphthalen-2-yloxy)carbonyl]-L-tyrosinamide
-
irreversible
N-[(3-bromo-4,5-dihydroisoxazol-5-yl)methyl]-Nalpha-[(pyridin-3-ylmethoxy)carbonyl]-L-tyrosinamide
-
irreversible
N-[(3-bromo-4,5-dihydroisoxazol-5-yl)methyl]-Nalpha-[(pyridin-4-ylmethoxy)carbonyl]-L-tyrosinamide
-
irreversible
N-[(3-bromo-4,5-dihydroisoxazol-5-yl)methyl]-Nalpha-[[(1,1-dioxido-1-benzothiophen-2-yl)methoxy]carbonyl]-5-hydroxy-L-tryptophanamide
-
irreversible
N-[(3-bromo-4,5-dihydroisoxazol-5-yl)methyl]-Nalpha-[[(1,1-dioxido-1-benzothiophen-2-yl)methoxy]carbonyl]-L-tyrosinamide
-
irreversible
N-[(3-bromo-4,5-dihydroisoxazol-5-yl)methyl]-Nalpha-[[5-(dimethylamino)naphthalen-2-yl]sulfonyl]-L-tyrosinamide
-
study on pharmacokinetics, pharmacodynamics, and bioavailability
N-[(6Z)-8-amino-2-[[(benzyloxy)carbonyl]amino]-8-oxooct-6-enoyl]glycine
-
-
N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-phenylalanyl-6-(dimethylsulfonio)-5-oxo-L-norleucine bromide
-
-
N-[(benzyloxy)carbonyl]-L-alanyl-6-(dimethylsulfonio)-5-oxo-L-norleucine bromide
-
-
N-[(benzyloxy)carbonyl]-L-alpha-aspartyl-6-(dimethylsulfonio)-5-oxo-L-norleucine bromide
-
-
N-[(benzyloxy)carbonyl]-L-isoleucyl-6-(dimethylsulfonio)-5-oxo-L-norleucine bromide
-
-
N-[(benzyloxy)carbonyl]-L-phenylalanyl-5-oxo-6-[(1,3,4,5-tetramethyl-1H-imidazol-3-ium-2-yl)sulfanyl]-L-norleucine
-
-
N-[(benzyloxy)carbonyl]-L-phenylalanyl-6-(diethylsulfonio)-5-oxo-L-norleucine
-
-
N-[(benzyloxy)carbonyl]-L-phenylalanyl-6-(dimethylsulfonio)-5-oxo-L-norleucine bromide
-
-
N-[(benzyloxy)carbonyl]-L-tryptophyl-6-(dimethylsulfonio)-5-oxo-L-norleucine bromide
-
-
N-[(benzyloxy)carbonyl]glycyl-6-(dimethylsulfonio)-5-oxo-L-norleucine bromide
-
-
N-[4-(4-cyclopentanecarbonylpiperazine-1-sulfonyl)-phenyl]acrylamide
-
-
N-[4-(4-cyclopropanecarbonylpiperazine-1-sulfonyl)-phenyl]acrylamide
-
-
N-[4-(4-phenylpiperazine-1-sulfonyl)phenyl]acrylamide
-
-
N-[4-(4-pyridin-2-ylpiperazine-1-sulfonyl)phenyl]acrylamide
-
-
N-[4-(aminomethyl)benzyl]-3-(5-[[[[(E)-2-phenylethenyl]sulfonyl](pyridin-2-ylmethyl)amino]methyl]-1,2,4-oxadiazol-3-yl)benzamide
-
-
N-[4-(piperazine-1-sulfonyl)phenyl]acrylamide
-
-
N-[4-(pyrrolidine-1-sulfonyl)phenyl]acrylamide
-
-
N-[4-methanesulfonylphenyl]acrylamide
-
-
N-[4-methoxyphenyl]acrylamide
-
-
N-[4-nitrophenyl]acrylamide
-
-
N-[4-phenoxyphenyl]acrylamide
-
-
N-[4-toluyl]acrylamide
-
-
N-[4-trifluoromethylphenyl]acrylamide
-
-
N-[4-[(1E)-3-oxo-3-(pyridin-3-yl)prop-1-en-1-yl]phenyl]acetamide
-
reversible, competitive with the acyl donor substrate
N-[4-[4-(2-phenylcyclopropanecarbonyl)piperazine-1-sulfonyl]phenyl]acrylamide
-
-
N-[4-[4-(2-trifluoromethylphenyl)piperazine-1-sulfonyl]-phenyl]acrylamide
-
-
N-[4-[4-(3-methylpyridin-2-yl)piperazine-1-sulfonyl]phenyl]-acrylamide
-
-
N-[4-[4-(3-phenylpropionyl)piperazine-1-sulfonyl]phenyl]-acrylamide
-
-
N-[4-[4-(3-phenylpropyl)piperazine-1-sulfonyl]phenyl]-acrylamide
-
-
N-[4-[4-(3-trifluoromethylpyridin-2-yl)piperazine-1-sulfonyl]phenyl]acrylamide
-
-
N-[4-[4-(4,4-difluoropiperidine-1-carbonyl)piperazine-1-sulfonyl]phenyl]acrylamide
-
-
N-[4-[4-(4-phenylbutyl)piperazine-1-sulfonyl]phenyl]-acrylamide
-
-
N-[4-[4-(6-methylpyridin-2-yl)piperazine-1-sulfonyl]phenyl]-acrylamide
-
-
N-[4-[4-(6-trifluoromethylpyridin-3-yl)piperazine-1-sulfonyl]phenyl]acrylamide
-
-
N-[4-[4-(adamantane-1-carbonyl)piperazine-1-sulfonyl]-phenyl]acrylamide
-
-
N-[4-[4-(octahydroisoquinoline-2-carbonyl)piperazine-1-sulfonyl]phenyl]acrylamide
-
-
N-[4-[4-(octahydroquinoline-1-carbonyl)piperazine-1-sulfonyl]phenyl]acrylamide
-
-
N-[4-[4-(piperidine-1-carbonyl)piperazine-1-sulfonyl]-phenyl]acrylamide
-
-
N-[4-[4-(pyrrolidine-1-carbonyl)piperazine-1-sulfonyl]-phenyl]acrylamide
-
-
N-[5-(4-cyclopropanecarbonylpiperazine-1-sulfonyl)-pyridin-2-yl]acrylamide
-
-
N-[5-[4-(adamantane-1-carbonyl)piperazine-1-sulfonyl]-pyridin-2-yl]acrylamide
-
-
N-[5-[4-(adamantane-1-carbonyl)piperazine-1-sulfonyl]-pyrimidin-2-yl]acrylamide
-
-
N-[[(5S)-3-bromo-4,5-dihydroisoxazol-5-yl]methyl]-5-fluoro-Na-[(quinolin-3-ylmethoxy)carbonyl]-L-tryptophanamide
-
-
N-{[(5S)-3-bromo-4,5-dihydro-1,2-oxazol-5-yl]methyl}-5-fluoro-Nalpha-[(quinolin-3-ylmethoxy)carbonyl]-L-tryptophanamide
-
-
N2-[(benzyloxy)carbonyl]-L-lysyl-6-(dimethylsulfonio)-5-oxo-L-norleucine bromide
-
-
N5-(3-methoxy-1,2,4-thiadiazol-5-yl)-N2-(phenoxycarbonyl)-L-ornithylglycine
-
irreversible, ratio kinact to Ki 0.55 micromol per min
N6-(3-methoxy-1,2,4-thiadiazol-5-yl)-N2-(phenoxycarbonyl)-L-lysylglycine
-
irreversible, ratio kinact to Ki 0.72 micromol per min
Na+
-
1 mM, 57% inhibition
Na-[(benzyloxy)carbonyl]-N-[(3-bromo-4,5-dihydroisoxazol-5-yl)methyl]-5-fluorotryptophanamide
-
-
Nalpha-[(benzyloxy)carbonyl]-N-[(3-bromo-4,5-dihydroisoxazol-5-yl)methyl]-L-tyrosinamide
naphthoquinone
-
0.015 mM, complete inhibition
NC-I052
-
irreversible inhibitor
o-phenanthroline
-
not reversible by Ca2+
ornithine
-
weak, suicide substrate in the presence of casein
p-chloromercuribenzoate
Pb(CH3COO)2
-
1 mM, 56% inhibition
Pb2+
-
5 mM Pb(CH3COO)2, 80% inhibition
phenyl methyl sulfonyl fluoride
-
10 mM, complete inhibition
propanolamine
-
-
putrescine
pyrrolidine-1-carboxylic acid (4-acryloylaminophenyl)-amide
-
-
quinolin-3-ylmethyl [(1S)-2-([[(5S)-3-bromo-4,5-dihydroisoxazol-5-yl]methyl]amino)-1-(4-hydroxybenzyl)-2-oxoethyl]carbamate
-
-
quinolin-3-ylmethyl [(1S)-2-[[(3-bromo-4,5-dihydroisoxazol-5-yl)methyl]amino]-1-(4-hydroxybenzyl)-2-oxoethyl]carbamate
-
-
R281
irreversible inhibitor
-
R283
irreversible inhibitor
-
S-nitroso-N-acetylpenicillamine
-
NO-donor, 8-16 mM, almost complete inhibition of transglutaminases 1 and 3, weak inhibition of transglutaminase 3
Sodium citrate
-
above 10 mM, complete inactivation
spermidine
spermine
SQAETYR
-
noncompetitive inhibition
SYAETYR
-
noncompetitive inhibition
Tb3+
-
noncompetitive inhibition of factor XIIIa, at high Ca2+-levels, not reversed by Ca2+
tert-butyl 3-(3-fluorophenyl)-2-[(2-hydrazino-2-oxoethyl)sulfanyl]-4-oxo-3,5,6,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidine-7(4H)-carboxylate
-
-
tert-butyl N-(3-methyl-1,2,4-thiadiazol-5-yl)-N2-(phenoxycarbonyl)-L-glutaminylglycinate
-
irreversible, ratio kinact to Ki 0.78 micromol per min
tert-butyl N6-acryloyl-N2-[(benzyloxy)carbonyl]-L-lysylglycinate
-
-
tert-butyl [4-[(1E)-3-(1H-benzotriazol-1-yl)-3-oxoprop-1-en-1-yl]phenyl]carbamate
-
reversible, competitive with the acyl donor substrate
tetrathionate
-
inactivation, not reversible by dithiothreitol
UTP
-
50% as effective as ATP
vitamin K1
-
0.015 mM, 10% inhibition
vitamin K2
-
0.015 mM, 75% inhibition
[(2-[[(benzyloxy)carbonyl]amino]-4-[5-(formylamino)-1,2,4-thiadiazol-3-yl]butanoyl)amino]acetic acid
-
-
[(4-[3-(aminocarbonyl)oxiran-2-yl]-2-[[(benzyloxy)carbonyl]amino]butanoyl)amino]acetic acid
-
-
[(5R,8S)-8-{[(benzyloxy)carbonyl]amino}-5-(methoxycarbonyl)-2,7-dioxo-9-phenylnonyl](dimethyl)sulfonium bromide
-
-
[([3-(aminocarbonyl)oxiran-2-yl][[(benzyloxy)carbonyl]amino]acetyl)amino]acetic acid
-
-
[1-(4-acryloylaminobenzenesulfonyl)piperidin-4-ylmethyl]-carbamic acid benzyl ester
-
-
[1-(4-acryloylaminobenzenesulfonyl)piperidin-4-yl]-carbamic acid benzyl ester
-
-
[2-[(4-acryloylaminobenzenesulfonyl)methylamino]ethyl]-methylcarbamic acid benzyl ester
-
-
[4-(4-acryloylpiperazine-1-sulfonyl)phenyl]carbamic acid benzyl ester
-
-
[4-[(4-aminophenyl)sulfonyl]piperazin-1-yl](cyclopropyl)methanone
-
-
[[(4E)-6-amino-2-[[(benzyloxy)carbonyl]amino]-6-oxohex-4-enoyl]amino]acetic acid
-
-
[[(5E)-7-amino-2-[[(benzyloxy)carbonyl]amino]-7-oxohept-5-enoyl]amino]acetic acid
-
-
[[(6Z)-8-amino-2-[[(benzyloxy)carbonyl]amino]-8-oxooct-6-enoyl]amino]acetic acid
-
-
additional information